Assignee
CATALYST BIOSCIENCES INC
US·17 granted patents·4 pending applications·185 citations·filing 1999–2021
Top patents by PatentIndex Score
21 records- 0195US7227009B2MT-SP1 polynucleotides and polypeptidesCATALYST BIOSCIENCES INC·Filed 2005·Granted Jun 5, 2007·35 cites·9 claims
- 0293US7030231B1Membrane type serine protease 1 (MT-SP1) and uses thereofCATALYST BIOSCIENCES INC·Filed 1999·Granted Apr 18, 2006·90 cites·6 claims
- 0391US7939304B2Mutant MT-SP1 proteases with altered substrate specificity or activityCATALYST BIOSCIENCES INC·Filed 2005·Granted May 10, 2011·17 cites·17 claims
- 0489US8383388B2Modified coagulation factor IX polypeptides and use thereof for treatmentCATALYST BIOSCIENCES INC·Filed 2007·Granted Feb 26, 2013·22 cites·65 claims
- 0588US9476037B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2013·Granted Oct 25, 2016·8 cites·30 claims
- 0688US9359598B2Mutant MT-SP1 proteases with altered substrate specificity or activityCATALYST BIOSCIENCES INC·Filed 2013·Granted Jun 7, 2016·7 cites·13 claims
- 0783US11203749B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2018·Granted Dec 21, 2021·1 cites·6 claims
- 0883US10258582B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2018·Granted Apr 16, 2019·2 cites·3 claims
- 0982US11266724B2Modified factor VII polypeptides for subcutaneous administration and on-demand treatmentCATALYST BIOSCIENCES INC·Filed 2021·Granted Mar 8, 2022·1 cites·17 claims
- 1081US10160961B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2016·Granted Dec 25, 2018·2 cites·26 claims
- 1173US10954501B2Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·0 cites·44 claims
- 1272US11401513B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Aug 2, 2022·0 cites·41 claims
- 1372US10716770B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2019·Granted Jul 21, 2020·0 cites·5 claims
- 1470US2021230570A1Modified factor ix polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1569US10781435B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2018·Granted Sep 22, 2020·0 cites·38 claims
- 1662US10982203B2Modified factor IX polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2016·Granted Apr 20, 2021·0 cites·42 claims
- 1759US2017071878A1Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 1857US2021069306A1Modified factor vii polypeptides for subcutaneous administration and on-demand treatmentCATALYST BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1954US9856467B2Modified factor X polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2014·Granted Jan 2, 2018·0 cites·35 claims
- 2049US2021238260A1Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptidesCATALYST BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2145US11491212B1Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia BCATALYST BIOSCIENCES INC·Filed 2018·Granted Nov 8, 2022·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when CATALYST BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →